# CENTER FOR DRUG EVALUATION AND RESEARCH

*APPLICATION NUMBER:*

**21-583**

## APPROVABLE LETTER(S)

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-583

Pfizer, Inc.
Attention: Daniel Chirby, M.Sc.
Associate Director
2800 Plymouth Road
Ann Arbor, MI 48105

Dear Mr. Chirby:

Please refer to your new drug application (NDA) dated June 30, 2003, received July 2, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Medroxyprogesterone Acetate Injection (104mg/0.65ml).

We also acknowledge receipt of your submissions dated July 07, October 22, 28(2), 29, 30, November 03, and December 03, 2003; January 06, February 18, 19, 23 (2), March 01, 10 (2), 15, 29, April 07, 14, 16, 21, 27, May 19, 20, 21, 25, June 15, July 23, 26, and July 28, 2004. These submissions were reviewed for this action.

We completed our review of this application, and it is approvable. Before this application may be approved, labeling must be finalized. To resolve this deficiency, submit revised draft labeling that addresses the issues raised in our July 15, 2004 correspondence. The revised draft labeling will serve as a basis for future discussions.

When you respond to the above deficiency, include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b). The safety update should include data from all non-clinical and clinical studies of the drug under consideration regardless of indication, dosage form, or dose level.

1. Describe in detail any significant changes or findings in the safety profile.

2. When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows:
   - Present new safety data from the studies for the proposed indication using the same format as the original NDA submission.
   - Present tabulations of the new safety data combined with the original NDA data.
   - Include tables that compare frequencies of adverse events in the original NDA with the retabulated frequencies described in the bullet above.
   - For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in clinical trials.

3. Present a retabulation of the reasons for premature study discontinuation by incorporating the drop-outs from the newly completed studies. Describe any new trends or patterns identified.

4. Provide case report forms and narrative summaries for each patient who died during a clinical study or who did not complete a study because of an adverse event. In addition, provide narrative summaries for serious adverse events.

5. Describe any information that suggests a substantial change in the incidence of common, but less serious, adverse events between the new data and the original NDA data.

6. Provide a summary of worldwide experience on the safety of this drug. Include an updated estimate of use for drug marketed in other countries.

Within 10 days after the date of this letter, you are required to amend this application, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. If you do not follow one of these options, we will consider your lack of response a request to withdraw the application under 21 CFR 314.65.

Under 21 CFR 314.102 (d), you may request a meeting or telephone conference with this division to discuss what steps need to be taken before the application may be approved.

The drug product may not be legally marketed until you have been notified in writing that this application is approved.

If you have any questions, call Charlene Williamson, Regulatory Project Manager, at (301) 827-4260.

Sincerely,

*{See appended electronic signature page}*

Donna Griebel, M.D.
Deputy Director
Division of Reproductive and Urologic Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

/s/

Donna Griebel
8/2/04 04:46:56 PM